Center "Vector" announced plans to release "Epivaccorona-N" into circulation

The release of the EpiVacCorona-N vaccine, produced by the Novosibirsk Center for Virology and Biotechnology Vector, is planned in the near future. This was announced by the deputy head of the center Tatyana Nepomnyashchikh.

"Epivaccorona-N" has not yet been released into civilian circulation, because only on Thursday we received permission. As soon as the series are developed by us and our industrial partners, Roszdravnadzor will give permission for the release of the series into civilian circulation. In the near future, it should go into circulation, ”TASS quoted Nepomnyashchikh as saying.

The Ministry of Health of the Russian Federation issued a registration certificate for the EpiVacCorona-N coronavirus vaccine last Thursday.

Earlier, the CEO of Vector, Rinat Maksyutov, reported that there were no fundamental differences between EpiVacKorona-N and the earlier EpiVacKorona. According to him, vaccines differ in technological features of production, which has become the main reason for the need for new clinical trials.

The EpiVacCorona coronavirus vaccine was registered on October 13, 2020. It became the second Russian vaccine against COVID-19 . Clinical trials of the drug began in early December. The drug entered civilian circulation on January 1, 2021.

"EpiVacCoron" was created on the basis of artificially synthesized short fragments of viral proteins. With their help, the immunity of a vaccinated person must learn to recognize virus cells.